Human recombinant interleukin-2 muteins
US4518584A · kind A · utility
292Cited by
3References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 20, 1983 |
| Grant date | May 21, 1985 |
| Priority date | — |
| Expiry date | Dec 20, 2003 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S930/142
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Muteins of biologically active proteins such as IFN-.beta. and IL-2 in which cysteine residues that are not essential to biological activity have been deleted or replaced with other amino acids to eliminate sites for intermolecular crosslinking or incorrect intramolecular disulfide bridge formation. These muteins are made via bacterial expression of mutant genes that encode the muteins that have been synthesized from the genes for the parent proteins by oligonucleotide-directed mutagenesis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.